Peter Stein is the Chairman and Chief Executive Officer of the Norgine Group. Norgine B.V., the primary subsidiary of the group, is a European specialist pharmaceutical company with operations throughout Europe, Australia and New Zealand. Peter also serves as the Chief Executive of Norgine Ventures, which provides financing solutions to innovative healthcare companies.
Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.
In addition to his role at Norgine, Peter is a non-executive Director of Agendia N.V., a molecular diagnostics company based in Amsterdam.
Peter Martin is the Chief Operating Officer at Norgine.
Peter has worked in the pharmaceutical industry in Europe and the US for the past thirty-eight years in a variety of sales, research and development and senior marketing and general management roles. He held a number of senior positions at Schering-Plough including UK General Manager and Vice President of Marketing at Schering’s US operations. He later went on to become Director of Operations Northern Europe for the Italian pharmaceutical company Menarini International before joining Norgine as its Chief Operating Officer in 2004.
Peter is Chairman of Arc Medical Design Limited, a majority owned subsidiary of Norgine, and Chairman of SpineVision.
Peter has a keen interest in the interface between Industry, Patients’ Associations and the individual patient and is a strong proponent for improved relations between these parties.
Peter has served on the ABPI Board of Management on two separate occasions in the 1990s and 2000s and is vociferous in his support for small companies.
Peter has an MA in Chemistry from Oxford University and an MBA from the Open University.
Christopher Bath is Norgine’s Chief Financial Officer.
Chris joined Norgine in 2014 from Shire plc, where he was Head of M&A. While at Shire, Chris led a number of transactions, including the $4.2 billion acquisition of Viropharma Inc.
His career in healthcare started in 2000, when he joined the Healthcare Investment Banking team at Rothschild, having qualified as a Chartered Accountant with Arthur Andersen. He spent the next 10 years at Rothschild working on and leading deals across the healthcare sector.
Chris originally trained as a scientist, reading Physics at Lady Margaret Hall, Oxford.
Paul Pay is the Chief Business Development Officer at Norgine.
Paul has over 35 years’ experience in the pharmaceutical industry in a range of commercial roles. These have covered sales, marketing, market research, licensing, business development and general management.
Paul joined Norgine in November 2002. Prior to that he worked for a number of companies covering Big Pharma (Wellcome, Fisons), “biotechs” (Xenova, Andaris) and a university spin-out (Aegis). He has worked in the UK and the USA.
Tara Barry is the Chief Human Resources Officer at Norgine.
Prior to joining Norgine in 2015, Tara has worked across a variety of industries for companies such Zurich Insurance, Hewlett Packard, Citigroup and Bertelsmann AG, as well as Roland Berger – Strategy Consultants.
During her twenty year career, Tara has lived and worked in Canada, the United States, Germany and Switzerland. Tara has a BA in Psychology from the University of Waterloo in Canada.
Kenneth Scrimgeour is the Chief Commercial Officer at Norgine.
Ken has worked in a variety of sales, marketing and general management roles in the pharmaceutical industry in Europe and the US for the past twenty-eight years; either in local roles or within regional and global positions. Ken has a BSc from Edinburgh University and he joined Norgine in 2004.
Philippe Caroff is the Chief Manufacturing Officer at Norgine.
Philippe joined Norgine in 2013 as Director for External Network, looking after all outsourced manufacturing activities and since mid-2015 has also taken responsibilities for Supply Chain & Distribution activities.
Prior to this, Philippe has worked for a number of companies including Ipsen, Cap Gemini, Seagram and BP, in various positions in Manufacturing, Supply chain, Purchasing activities and also in Research & Development, with more than 15 years in the Pharmaceutical industry. Philippe graduated from Ecole des Mines de St Etienne in General Engineering.
Alastair Benbow is the Chief Development and Medical Officer at Norgine.
Alastair is a physician with over 25 years of experience in the pharmaceutical industry.
Prior to joining Norgine in September 2016, Alastair worked for a number of companies including Fisons, Genentech, Synthelabo and spent 12 years working at GlaxoSmithKline (GSK). During his time at GSK, he held positions as UK Medical Director, Head of European Government Affairs, Head of Psychiatry Development, European Medical Director and SVP Global Safety and Pharmacovigilance and EU QPPV.
For three years, he held the role of Executive Director for the non-profit organisation, the European Brain Council and for three years he was Chief Medical Officer at Kinapse, where he led the Regulatory, Safety and Medical functions. He is a fellow of the Royal College of Physicians of Ireland and a Fellow of the Faculty of Pharmaceutical Medicine. In 2017 Alastair was appointed Chair of the Ethics and Practice Committee of the Faculty of Pharmaceutical Medicine.
Robert Steele is the Director of Digital Transformation at Norgine
Rob joined Norgine in 2008 as IT Director with responsibility for all computer systems, infrastructure and networks across the group.
Rob has over 30 years experience working in all areas of information technology, 20 years of which in the pharmaceutical and healthcare sectors. His diverse experience in these sectors includes; generic pharmaceuticals, medical devices, prison hospitals and outsourced pathology services.
Prior to this Rob worked extensively in the automotive industry for companies such as; Jaguar Land Rover, Daewoo, Mazda, General Motors and Mercedes Benz.
We use strictly necessary, performance and functionality cookies to give you the best experience while using this website. We do not employ any marketing cookies on this website. Only continue if you accept. AcceptRead more